Notice of Correction to Eligibility Information in RFA-AG-19-010 "Alzheimer Centers for Discovery of New Medicines (U54 Clinical Trial Not Allowed)"

Sponsor: National Institute on Aging

NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)

Sponsor: National Library of Medicine

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional) (RFA-MH-19-135)

Sponsor: National Institutes of Health

Award: Issuing IC and partner components intend to commit an estimated total of $10 million to fund six to nine awards.

Due Date: October 9, 2018; September 26, 2019 and September 28, 2020, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Alzheimer Centers for Discovery of New Medicines (U54 Clinical Trial Not Allowed)

Sponsor: National Institute on Aging

Award: NIA intends to commit $15 million in FY 2019 to fund one or two awards.

Due Date: February 1, 2019, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Biomarkers Across Neurodegenerative Diseases (BAND)

Sponsor: Alzheimer's Association/Michael J. Fox Foundation/Weston Brain Institute/Alzheimer's Research UK Award

Award: $150,000 up to two years.

Due Date: Letter of Intent due September 10, 2018, 6 p.m. EST; if invited, full application due December 1, 2018, 6 p.m. EST

Genomic Innovator Award (R35 Clinical Trial Optional)

Sponsor: National Human Genome Research Institute

Award: NHGRI intends to commit $1 million in FY 2019 to fund two awards.

Due Date: October 30, 2018; October 30, 2019; October 30, 2020), by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Regenerative Medicine Innovation Projects (RMIP) Investigator-Initiated Studies (Collaborative U01 Clinical Trial Not Allowed)

Sponsor: National Institutes of Health

Award: NIH intends to commit total funds of up to $28 million in FY 2019 and anticipates issuing up to 15 awards for projects submitted to this FOA and the three companion funding opportunities listed in this FOA.

Due Date: October 19, 2018, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Regenerative Medicine Innovation Projects (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required)

Sponsor: National Institutes of Health

Award: NIH intends to commit total funds of up to $28 million in FY 2019 and anticipates issuing up to 15 awards for projects submitted to this FOA and the three companion funding opportunities listed in the FOA.

Due Date: October 19, 2018, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Regenerative Medicine Innovation Projects (RMIP) (UT2 - Clinical Trial Not Allowed) (RFA-HL-18-033)

Sponsor: National Institutes of Health

Award: NIH intends to commit total funds of up to $28 million in FY 2019 and anticipates issuing up to 15 awards for clinical trial and non-clinical trial projects submitted to the FOA and the three companion funding opportunities listed in the FOA.

Due Date: October 19, 2018, by 5 p.m. local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Regenerative Medicine Innovation Projects (RMIP) (U44 - Clinical Trial Not Allowed) (RFA-HL-18-035)

Sponsor: National Institutes of Health

Award: NIH intends to commit total funds of up to $28 million in FY 2019 and anticipates issuing up to 15 awards for projects submitted to this FOA and the three companion funding opportunities listed in the FOA.

Due Date: October 19, 2018, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03 Clinical Trial Optional)

Sponsor: National Institute on Aging

Award: NIA intends to commit $1.7 million in FY 2019 to fund approximately 15 awards.

Due Date: October 23, 2018, by 5 p.m. local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Novel Approaches for Relating Genetic Variation to Function and Disease (R21 Clinical Trial Not Allowed)

Sponsor: National Human Genome Research Institute

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Novel Approaches for Relating Genetic Variation to Function and Disease (R01 Clinical Trial Not Allowed)

Sponsor: National Human Genome Research Institute National Institute of Mental Health

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR) (R41/R42 - Clinical Trials Not Allowed)

Sponsor: National Institutes of Health

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR) (R43/R44 - Clinical Trial Not Allowed)

Sponsor: National Institutes of Health

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.